Hycamtin - Big Patent Expirations of 2010

Drug: Hycamtin
Company: GlaxoSmithKline
Indication: Ovarian and small-cell lung cancer
Expiration Date: May 28/Pediatric Exclusivity through Nov. 28

Summary: The '758 patent covering Hycamtin enjoys pediatric exclusivity until November. However, according to the [email protected] website, no generic company has tentative approval for Hycamtin, which is used to treat ovarian and small-cell lung cancer. The product had sales of $72 million in 2009, according to a GSK earnings statement. Teva has tried to get samples of the drug to see if it can make a copy, but GSK has refused. The FTC said last fall it would look into to see whether GSK's actions unfairly thwart competition.

Hycamtin - Big Patent Expirations of 2010

Suggested Articles

AveXis' ex-CSO is "prepared to assert his rights and defend his conduct accordingly," a statement from a lawyer who recently represented Elon…

Hikma says it has picked up some pipeline products and nasal and sublingual spray equipment from Insys Therapeutics' bankruptcy.

AstraZeneca is still stinging after its SGLT2 drug Farxiga was waved off in Type 1 diabetes, but new heart failure data could ease the pain.